Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns

Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.